Cargando…
Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors
Strategies to induce p53 activation in wtp53-retaining tumors carry high potential in cancer therapy. Nutlin, a potent highly selective MDM2 inhibitor, induces non-genotoxic p53 activation. Although Nutlin shows promise in promoting cell death in hematopoietic malignancies, a major roadblock is that...
Autores principales: | Vaseva, A V, Yallowitz, A R, Marchenko, N D, Xu, S, Moll, U M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3122118/ https://www.ncbi.nlm.nih.gov/pubmed/21562588 http://dx.doi.org/10.1038/cddis.2011.39 |
Ejemplares similares
-
Repercussion of Mitochondria Deformity Induced by Anti-Hsp90 Drug 17AAG in Human Tumor Cells
por: Vishal, Chaturvedi, et al.
Publicado: (2011) -
Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma?()
por: Mehta, Adi, et al.
Publicado: (2013) -
Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer
por: Zajac, Magdalena, et al.
Publicado: (2010) -
A Novel Mechanism of 17-AAG Therapeutic Efficacy on HSP90 Inhibition in MYCN-Amplified Neuroblastoma Cells
por: Hanna, Reine, et al.
Publicado: (2021) -
HSP90 inhibitor 17AAG attenuates sevoflurane-induced neurotoxicity in rats and human neuroglioma cells via induction of HSP70
por: Liu, Min, et al.
Publicado: (2020)